Abstract: There is disclosed anti-PD-L1 IgG class antibodies that have an improved ability to be manufactured at higher yields. More specifically, there is disclosed human antibodies that bind PD-L1, PD-L1-binding fragments that can be manufactured at higher yields.

Abstract: There is disclosed compositions and methods relating to or derived from anti-PD-L1 antibodies. More specifically, there is disclosed fully human antibodies that bind PD-L1, PD-L1-binding fragments and derivatives of such antibodies, and PD-L1-binding polypeptides comprising such fragments. Further still, there is disclosed nucleic acids encoding such antibodies, antibody fragments and derivatives and polypeptides, cells comprising such polynucleotides, methods of making such antibodies, antibody fragments and derivatives and polypeptides, and methods of using such antibodies, antibody fragments and derivatives and polypeptides, including methods of treating or diagnosing subjects having PD-L1 related disorders or conditions, including various inflammatory disorders and various cancers.

Abstract: The present disclosure provides fully human antibodies that specifically bind the spike (S) protein of the SARS-CoV-2 coronavirus with high affinity, or antigen-binding proteins derived from such antibodies, and uses thereof. Included are anti-spike protein antibodies, antibody fragments, and single-chain antibodies, that are coronavirus neutralizing antibodies, as well as pharmaceutical compositions that include such antibodies and antibody fragments. Methods for using the anti-spike protein antibodies include methods of treating or preventing infection with a coronavirus, such as the SARS-CoV-2 coronavirus, by administering an antibody or antibody fragment as disclosed herein, including by intranasal delivery. Methods and compositions for treating or preventing coronavirus infection by administering a composition that includes a nucleic acid construct that encodes a neutralizing antibody are also provided.

Abstract: The present disclosure provides antigen-binding proteins, such as fully human antibodies, that specifically bind the spike (S) protein of the SARS-CoV-2 coronavirus and uses thereof. In various embodiments, the anti-spike protein antibodies are neutralizing antibodies that prevent binding of the SARS-CoV-2 coronavirus to a target cell expressing the ACE2 protein. Included are anti-spike protein antibodies, antibody fragments, and single-chain antibodies, as well as pharmaceutical compositions that include such antibodies and antibody fragments. Also provided herein are nucleic acids and recombinant expression vectors that encode the anti-spike protein antibodies and antibody fragments disclosed herein and transgenic cells transected with such nucleic acids and expression vectors. Further provided are methods for preparing and using such anti-spike protein antibodies.

Abstract: There is disclosed compositions and methods relating to or derived from anti-CD38 antibodies. More specifically, there is disclosed fully human antibodies that bind CD38, CD38-antibody binding fragments and derivatives of such antibodies, and CD38-binding polypeptides comprising such fragments. Further still, there is disclosed nucleic acids encoding such antibodies, antibody fragments and derivatives and polypeptides, cells comprising such polynucleotides, methods of making such antibodies, antibody fragments and derivatives and polypeptides, and methods of using such antibodies, antibody fragments and derivatives and polypeptides, including methods of treating a disease.

Abstract: There is disclosed compositions and methods relating to or derived from anti-CD123 antibodies. More specifically, there is disclosed fully human antibodies that bind CD123, CD123-antibody binding fragments and derivatives of such antibodies, and CD123-binding polypeptides comprising such fragments. Further still, there is disclosed nucleic acids encoding such antibodies, antibody fragments and derivatives and polypeptides, cells comprising such polynucleotides, methods of making such antibodies, antibody fragments and derivatives and polypeptides, and methods of using such antibodies, antibody fragments and derivatives and polypeptides, including methods of treating a disease.

Abstract: The present disclosure provides PD-1 binding proteins, particularly anti-PD-1 antibodies, or antigen-binding portions thereof, that specifically bind PD-1 and uses thereof. In one embodiment, the anti-PD-1 antibody comprises an antigen binding portion that binds a human PD-1 epitope or a non-human PD-1 epitope. Various aspects of the anti-PD-1 antibodies relate to antibody fragments, single-chain antibodies, pharmaceutical compositions, nucleic acids, recombinant expression vectors, host cells, and methods for preparing and using such anti-PD-1 antibodies. Methods for using the anti-PD-1 antibodies include in vitro and in vivo methods for binding PD-1, blocking interaction between PD-1 and PD-L1, detecting PD-1, and treating diseases associated with PD-L1 over-expression or PD-L1 detrimental expression.

Abstract: The present disclosure provides methods for treating a subject having a coronavirus infection by administering a composition that includes a sACE2 polypeptide to the lungs of a subject infected with a coronavirus. The sACE2 polypeptide includes the extracellular portion of the human ACE2 polypeptide and acts as a decoy, binding the spike (S) protein of coronavirus and thereby preventing the interaction of the S protein with membrane-associated ACE2 expressed on pulmonary cells, thus disrupting the infection process. The sACE2 polypeptide is derived from human ACE2, preventing potential immune reactions of the subject to the therapeutic polypeptide. The sACE2 polypeptide is administered locally to the site of the pathology, avoiding potential adverse effects of systemic delivery.

Abstract: The present disclosure provides fully human anti-LAG3 IgG class antibodies engineered to have amino acid sequence in their heavy chain variable region and/or light chain variable region to improve antigen binding, cell binding, T cell activation and cytokine release capabilities.

Abstract: There is disclosed compositions and methods relating to or derived from anti-PD-1 antibodies. More specifically, there is disclosed fully human antibodies that bind PD-1, PD-1-binding fragments and derivatives of such antibodies, and PD-1-binding polypeptides comprising such fragments. Further still, there is disclosed nucleic acids encoding such antibodies, antibody fragments and derivatives and polypeptides, cells comprising such polynucleotides, methods of making such antibodies, antibody fragments and derivatives and polypeptides, and methods of using such antibodies, antibody fragments and derivatives and polypeptides, including methods of treating or diagnosing subjects having PD-1 related disorders or conditions, including various inflammatory disorders and various cancers.

Abstract: The present disclosure provides anti-CD38 antigen-binding proteins such as fully human anti-CD38 IgG class antibodies each having an altered amino acid sequence in their heavy chain variable region and/or light chain variable region compared to their wild type parent antibody. The present disclosure provides engineered CD38 binding proteins, particularly anti-CD38 variant antibodies, or antigen-binding portions thereof, that specifically bind CD38, and uses thereof. The disclosed anti-CD38 antigen-binding proteins and antibodies have been engineered to exhibit improved characteristics compared to the parent antibody, such as improved binding to CD38 antigen, improved binding to CD38-expressing cells, and/or higher levels of cytotoxicity. The anti-CD38 variant antibodies can cross-react (bind) with cynomolgus CD38.

Abstract: There is disclosed compositions and methods relating to or derived from anti-WISP1 antibodies. More specifically, there is disclosed fully human antibodies that bind WISP1, WISP1-binding fragments and derivatives of such antibodies, and WISP1-binding polypeptides comprising such fragments. Further still, there is disclosed nucleic acids encoding such antibodies, antibody fragments and derivatives and polypeptides, cells comprising such polynucleotides, methods of making such antibodies, antibody fragments and derivatives and polypeptides, and methods of using such antibodies, antibody fragments and derivatives and polypeptides, including methods of treating or diagnosing subjects having WISP1 related disorders or conditions. There is also disclosed a method for treating or preventing various cancers or inflammatory diseases and various diseases of the heart, bone/joints or lung.

Abstract: There is disclosed an antibody drug conjugate (ADC) having an IgG antibody that binds to a CD38 target conjugated at a Cys site in the hinge region of an IgG antibody. There is further disclosed a method for treating multiple myeloma comprising providing an effective amount of a CD38 ADC.

Abstract: There is disclosed compositions and methods relating to or derived from anti-PD-1 antibodies. More specifically, there is disclosed fully human antibodies that bind PD-1, PD-1-binding fragments and derivatives of such antibodies, and PD-1-binding polypeptides comprising such fragments. Further still, there is disclosed nucleic acids encoding such antibodies, antibody fragments and derivatives and polypeptides, cells comprising such polynucleotides, methods of making such antibodies, antibody fragments and derivatives and polypeptides, and methods of using such antibodies, antibody fragments and derivatives and polypeptides, including methods of treating or diagnosing subjects having PD-1 related disorders or conditions, including various inflammatory disorders and various cancers.

Abstract: There is disclosed compositions and methods relating to anti-VEGFR2 antibodies. More specifically, there is disclosed fully human antibodies that bind VEGFR2, VEGFR2-binding fragments and derivatives of such antibodies, and VEGFR2-binding polypeptides comprising such fragments. Further still, there is disclosed antibody fragments and derivatives and polypeptides, and methods of using such antibodies, antibody fragments and derivatives and polypeptides, including methods of treating or diagnosing subjects having various cancers.

Abstract: There is disclosed compositions and methods relating to or derived from anti-CD137 antibodies. More specifically, there is disclosed fully human antibodies that bind CD137, CD137-antibody binding fragments and derivatives of such antibodies, and CD137-binding polypeptides comprising such fragments. Further still, there is disclosed nucleic acids encoding such antibodies, antibody fragments and derivatives and polypeptides, cells comprising such polynucleotides, methods of making such antibodies, antibody fragments and derivatives and polypeptides, and methods of using such antibodies, antibody fragments and derivatives and polypeptides, including methods of treating a disease requiring either stimulation of immune responses or suppression. Diseases amenable to treatment is selected from the group consisting of cancers, autoimmune diseases and viral infections.

Abstract: There is disclosed compositions and methods relating to or derived from anti-c-Met antibodies. More specifically, there is disclosed fully human antibodies that bind c-Met, c-Met-binding fragments and derivatives of such antibodies, and c-Met-binding polypeptides comprising such fragments. Further still, there is disclosed nucleic acids encoding such antibodies, antibody fragments and derivatives and polypeptides, cells comprising such polynucleotides, methods of making such antibodies, antibody fragments and derivatives and polypeptides, and methods of using such antibodies, antibody fragments and derivatives and polypeptides, including methods of treating or diagnosing subjects having c-Met related disorders or conditions, including various inflammatory disorders and various cancers.

Abstract: There is disclosed compositions and methods relating to or derived from anti-CTLA4 antibodies. More specifically, there is disclosed fully human antibodies that bind CTLA4, CTLA4-antibody binding fragments and derivatives of such antibodies, and CTLA4-binding polypeptides comprising such fragments. Further still, there is disclosed nucleic acids encoding such antibodies, antibody fragments and derivatives and polypeptides, cells comprising such polynucleotides, methods of making such antibodies, antibody fragments and derivatives and polypeptides, and methods of using such antibodies, antibody fragments and derivatives and polypeptides, including methods of treating a disease requiring either stimulation of immune responses or suppression.

Abstract: The present disclosure provides BCMA binding proteins, particularly anti-BCMA antibodies, or antigen-binding portions thereof, that specifically bind BCMA and uses thereof. In one embodiment, the anti-BCMA antibody comprises an antigen binding portion that binds a human BCMA epitope and blocks binding (e.g, inhibits binding) of human APRIL and/or human BAFF to the human BCMA epitope. Various aspects of the anti-BCMA antibodies relate to antibody fragments, single-chain antibodies, pharmaceutical compositions, nucleic acids, recombinant expression vectors, host cells, and methods for preparing and using such anti-BCMA antibodies. Methods for using the anti-BCMA antibodies include in vitro and in vivo methods for binding BCMA, detecting BCMA and treating diseases associated with BCMA over-expression.

Abstract: There is disclosed an antibody drug conjugate (ADC) having an IgG antibody that binds to a CD38 target conjugated at a Cys site in the hinge region of an IgG antibody. There is further disclosed a method for treating multiple myeloma comprising providing an effective amount of a CD38 ADC.